|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aure MR, Vitelli V, Jernström S, Kumar S,
Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, et
al: Integrative clustering reveals a novel split in the Luminal A
subtype of breast cancer with impact on outcome. Breast Cancer Res.
19:442017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ Panel members:
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jagsi R, Raad RA, Goldberg S, Sullivan T,
Michaelson J, Powell SN and Taghian AG: Locoregional recurrence
rates and prognostic factors for failure in node-negative patients
treated with mastectomy: Implications for postmastectomy radiation.
Int J Radiat Oncol Biol Phys. 62:1035–1039. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
breast cancer study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDermott AM, Miller N, Wall D, Martyn LM,
Ball G, Sweeney KJ and Kerin MJ: Identification and validation of
oncologic miRNA biomarkers for Luminal A-like breast cancer. PLoS
One. 9:e870322014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ross JS, Hatzis C, Symmans WF, Pusztai L
and Hortobágyi GN: Commercialized multigene predictors of clinical
outcome for breast cancer. Oncologist. 13:477–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma XJ, Wang Z, Ryan PD, Isakoff SJ,
Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT,
et al: A two-gene expression ratio predicts clinical outcome in
breast cancer patients treated with tamoxifen. Cancer Cell.
5:607–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang JC, Wooten EC, Tsimelzon A,
Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK,
Chamness GC, Allred DC and O'Connell P: Gene expression profiling
for the prediction of therapeutic response to docetaxel in patients
with breast cancer. Lancet. 362:362–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang JC, Wooten EC, Tsimelzon A,
Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin
S, Osborne CK, et al: Patterns of resistance and incomplete
response to docetaxel by gene expression profiling in breast cancer
patients. J Clin Oncol. 23:1169–1177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cleator S, Tsimelzon A, Ashworth A,
Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK,
O'Connell P and Chang JC: Gene expression patterns for doxorubicin
(Adriamycin) and cyclophosphamide (cytoxan) (AC) response and
resistance. Breast Cancer Res Treat. 95:229–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peintinger F, Anderson K, Mazouni C,
Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF and Pusztai
L: Thirty-gene pharmacogenomic test correlates with residual cancer
burden after preoperative chemotherapy for breast cancer. Clin
Cancer Res. 13:4078–4082. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu R, Wang X, Chen GY, Dalerba P, Gurney
A, Hoey T, Sherlock G, Lewicki J, Shedden K and Clarke MF: The
prognostic role of a gene signature from tumorigenic breast-cancer
cells. N Engl J Med. 356:217–226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Desmedt C, Piette F, Loi S, Wang Y,
Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y,
d'Assignies MS, et al: Strong time dependence of the 76-gene
prognostic signature for node-negative breast cancer patients in
the TRANSBIG multicenter independent validation series. Clin Cancer
Res. 13:3207–3214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu
J, et al: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dowsett M, Cuzick J, Wale C, Forbes J,
Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, et al:
Prediction of risk of distant recurrence using the 21-gene
recurrence score in node-negative and node-positive postmenopausal
patients with breast cancer treated with anastrozole or tamoxifen:
A TransATAC study. J Clin Oncol. 28:1829–1834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mamounas EP, Tang G, Fisher B, Paik S,
Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL and
Wolmark N: Association between the 21-gene recurrence score assay
and risk of locoregional recurrence in node-negative, estrogen
receptor-positive breast cancer: Results from NSABP B-14 and NSABP
B-20. J Clin Oncol. 28:1677–1683. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang G, Shak S, Paik S, Anderson SJ,
Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL and Wolmark
N: Comparison of the prognostic and predictive utilities of the
21-gene recurrence score assay and Adjuvant! for women with
node-negative, ER-positive breast cancer: Results from NSABP B-14
and NSABP B-20. Breast Cancer Res Treat. 127:133–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albain KS, Barlow WE, Shak S, Hortobagyi
GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, et al: Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: A
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dowsett M, Sestak I, Lopez-Knowles E,
Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C and
Cuzick J: Comparison of PAM50 risk of recurrence score with
oncotype DX and IHC4 for predicting risk of distant recurrence
after endocrine therapy. J Clin Oncol. 31:2783–2790. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu X, Ying J, Wang F, Wang J and Yang H:
Estrogen receptor, progesterone receptor, and human epidermal
growth factor receptor 2 status in invasive breast cancer: A 3,198
cases study at National cancer center, China. Breast Cancer Res
Treat. 147:551–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thomas JG, Olson JM, Tapscott SJ and Zhao
LP: An efficient and robust statistical modeling approach to
discover differentially expressed genes using genomic expression
profiles. Genome Res. 11:1227–1236. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Xie J, Yang J, Fennell A, Zhang C
and Ma Q: QUBIC: A bioconductor package for qualitative
biclustering analysis of gene co-expression data. Bioinformatics.
33:450–452. 2017.PubMed/NCBI
|
|
27
|
Chen X, Liu L, Wang Y, Liu B, Zeng D, Jin
Q, Li M, Zhang D, Liu Q and Xie H: Identification of breast cancer
recurrence risk factors based on functional pathways in tumor and
normal tissues. Oncotarget. 8:20679–20694. 2017.PubMed/NCBI
|
|
28
|
Choi BY, Bair E and Lee JW: Nearest
shrunken centroids via alternative genewise shrinkages. PLoS One.
12:e01710682017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ravindranath A, O'Connell A, Johnston PG
and El-Tanani MK: The role of LEF/TCF factors in neoplastic
transformation. Curr Mol Med. 8:38–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dey N, Barwick BG, Moreno CS,
Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C,
Kerstann KF, Sledge GW Jr, et al: Wnt signaling in triple negative
breast cancer is associated with metastasis. BMC Cancer.
13:5372013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vijaya Kumar A, Salem Gassar E, Spillmann
D, Stock C, Sen YP, Zhang T, Van Kuppevelt TH, Hülsewig C,
Koszlowski EO, Pavao MS, et al: HS3ST2 modulates breast cancer cell
invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation
of protease and cadherin expression. Int J Cancer. 135:2579–2592.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naidu R, Yip CH and Taib NA: Genetic
variations in transcription factor 7-like 2 (TCF7L2) gene:
Association of TCF7L2 rs12255372(G/T) or rs7903146(C/T) with breast
cancer risk and clinico-pathological parameters. Med Oncol.
29:411–417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burwinkel B, Shanmugam KS, Hemminki K,
Meindl A, Schmutzler RK, Sutter C, Wappenschmidt B, Kiechle M,
Bartram CR and Frank B: Transcription factor 7-like 2 (TCF7L2)
variant is associated with familial breast cancer risk: A
case-control study. BMC Cancer. 6:2682006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bodhini D, Radha V, Dhar M, Narayani N and
Mohan V: The rs12255372(G/T) and rs7903146(C/T) polymorphisms of
the TCF7L2 gene are associated with type 2 diabetes mellitus in
Asian Indians. Metabolism. 56:1174–1178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Crispo A, Augustin LS, Grimaldi M,
Nocerino F, Giudice A, Cavalcanti E, Di Bonito M, Botti G, De
Laurentiis M, Rinaldo M, et al: Risk differences between
prediabetes and diabetes according to breast cancer molecular
subtypes. J Cell Physiol. 232:1144–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Müller HM, Widschwendter A, Fiegl H,
Ivarsson L, Goebel G, Perkmann E, Marth C and Widschwendter M: DNA
methylation in serum of breast cancer patients: An independent
prognostic marker. Cancer Res. 63:7641–7645. 2003.PubMed/NCBI
|
|
39
|
Mukherjee N, Bhattacharya N, Alam N, Roy
A, Roychoudhury S and Panda CK: Subtype-specific alterations of the
Wnt signaling pathway in breast cancer: Clinical and prognostic
significance. Cancer Sci. 103:210–220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang WJ, Yao Y, Jiang LL, Hu TH, Ma JQ,
Liao ZJ, Yao JT, Li DF, Wang SH and Nan KJ: Knockdown of lymphoid
enhancer factor 1 inhibits colon cancer progression in vitro and in
vivo. PLoS One. 8:e765962013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin AY, Chua MS, Choi YL, Yeh W, Kim YH,
Azzi R, Adams GA, Sainani K, van de Rijn M, So SK and Pollack JR:
Comparative profiling of primary colorectal carcinomas and liver
metastases identifies LEF1 as a prognostic biomarker. PLoS One.
6:e166362011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Delaunay S, Rapino F, Tharun L, Zhou Z,
Heukamp L, Termathe M, Shostak K, Klevernic I, Florin A, Desmecht
H, et al: Elp3 links tRNA modification to IRES-dependent
translation of LEF1 to sustain metastasis in breast cancer. J Exp
Med. 213:2503–2523. 2016. View Article : Google Scholar : PubMed/NCBI
|
